AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.008

0.000

Volume:3.98M

Turnover:29.65K

Market Cap:34.70M

PE:-0.45

High:0.008

Open:0.008

Low:0.007

Close:0.008

52wk High:0.040

52wk Low:0.007

Shares:4.34B

Float Shares:3.34B

Volume Ratio:0.21

T/O Rate:0.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-174.71%

ROA:-44.61%

PB:1.41

PE(LYR):-0.45

Loading ...

Overview Company News Filings

Radiopharm Says Interim Phase 2b Rad101 PET Trial Meets Primary Endpoint with 93% MRI Concordance

Press Release: Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of Rad101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics Holds General Meeting; All Resolutions Carried by Poll

Radiopharm Reports Positive Phase 1 Imaging Data for Rad301 in Pancreatic Cancer Patients

Radiopharm Theranostics - Significant Tumor Uptake Observed in All Evaluable Pancreatic Cancer Patients

THOMSON REUTERS

Radiopharm Theranostics - Positive Safety and Favorable Biodistribution Observed in All Subjects Dosed with Rad301

THOMSON REUTERS

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of Rad301 in Patients with Pancreatic Ductal Adenocarcinoma

THOMSON REUTERS

Radiopharm Theranostics - no Dividends Paid or Declared for Year Ended 30 June 2026

THOMSON REUTERS

Radiopharm Theranostics - Prelim Loss for the Year Attributable up 50.3% to A$55.15 Mln for Year Ended 30 June 2026

THOMSON REUTERS

Radiopharm Theranostics - FY Prelim Revenue from Contracts with Customers A$2.8 Mln

THOMSON REUTERS

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of Betabart (Rv-01) in B7-H3 Expressing Solid Tumors

THOMSON REUTERS

Radiopharm Theranostics Advances 177Lu-Rad202 Phase 1 HEAT Trial to 180 mCi Dose Cohort After DSMC Review

Radiopharm Theranostics - Rad202 Study Shows Clinical Proof-of-Concept with Positive Safety and Biodistribution

THOMSON REUTERS

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-Rad202 Phase 1 Heat Clinical Trial

THOMSON REUTERS

Radiopharm Theranostics - Advances Rad202 Phase 1 Trial to 180Mci Dose in Her2-Positive Advanced Solid Tumors

THOMSON REUTERS

Radiopharm Teams up with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial

Radiopharm Theranostics - Rad101 Receives FDA Fast Track Designation for Brain Metastases Diagnosis

THOMSON REUTERS

Radiopharm Theranostics - Schedules End-of-Phase 2 FDA Meeting for Rad101 Phase 3 Trial on Oct 1, 2026

THOMSON REUTERS

Radiopharm Theranostics to Meet With US FDA on Phase 3 Brain Metastases Diagnosis Trial

MT Newswires Live

Radiopharm Theranostics Ltd-Rad to Meet with US FDA to Align on Rad 101 Phase 3 Trial

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/RAD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.008,"timestamp":1789539120000,"preClose":0.008,"halted":0,"volume":3982978,"delay":0,"changeRate":0,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.0179,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-16 16:12:00 AEST","open":0.008,"high":0.008,"low":0.007,"amount":29651,"amplitude":0.125,"askPrice":0.008,"askSize":1455380,"bidPrice":0.007,"bidSize":6221721,"shortable":3,"etf":0,"ttmEps":-0.0179,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.008,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.209622,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.008,"auctionPrice":0.008,"auctionVolume":798548,"auction":3,"marketStatus":"盘后竞价","timestamp":1789538822869}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-44.61%","roe":"-174.71%","lyrEps":-0.0179,"volumeRatio":0.209622,"shares":4337549000,"dividePrice":0,"high":0.008,"amplitude":0.125,"preClose":0.008,"low":0.007,"week52Low":0.007,"pbRate":"1.41","psRate":"2.57","week52High":0.04,"institutionHeld":0,"latestPrice":0.008,"committee":0.620852,"eps":-0.0179,"divideRate":0,"volume":3982978,"delay":0,"ttmEps":-0.0179,"open":0.008,"prevYearClose":0.025,"prevWeekClose":0.008,"prevMonthClose":0.01,"prevQuarterClose":0.019,"fiveDayClose":0.009,"twentyDayClose":0.012,"sixtyDayClose":0.019,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667572665","title":"Radiopharm Says Interim Phase 2b Rad101 PET Trial Meets Primary Endpoint with 93% MRI Concordance","url":"https://stock-news.laohu8.com/highlight/detail?id=2667572665","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667572665?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:05","pubTimestamp":1789387544,"startTime":"0","endTime":"0","summary":"Radiopharm says interim Phase 2b RAD101 PET trial meets primary endpoint with 93% MRI concordanceRadiopharm Theranostics flagged positive interim Phase 2b imaging data for RAD101 in suspected recurren","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL54ZDHc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BQXX3C00.GBP","SG9999014039.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","SG9999014005.SGD","IE00BQXX3F31.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","SG9999014013.SGD","BCDF","IE00B3QW5Z07.USD","RAD.AU","IE00BN0W2T93.GBP","LU2095319765.USD","BK4588","BK7067","LU0314104364.USD","BK4585","IE00BN0W2W23.USD","SG9999014021.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667037663","title":"Press Release: Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of Rad101 at 2026 Society of Neuro-Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2667037663","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667037663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":"RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpointMeeting with FDA planned on October 1(st) to align on RAD101Phase 3 pivotal trial pro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRS","RADX","BK7067","BK4139","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666552177","title":"Radiopharm Theranostics Holds General Meeting; All Resolutions Carried by Poll","url":"https://stock-news.laohu8.com/highlight/detail?id=2666552177","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666552177?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:02","pubTimestamp":1789128139,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics holds general meeting; all resolutions carried by pollRadiopharm Theranostics held a general meeting on Friday.Shareholders ratified the prior issue of First Tranche Placement ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL9bVlB2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666551587","title":"Radiopharm Reports Positive Phase 1 Imaging Data for Rad301 in Pancreatic Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666551587","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666551587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:04","pubTimestamp":1788951890,"startTime":"0","endTime":"0","summary":"Radiopharm reports positive Phase 1 imaging data for RAD301 in pancreatic cancer patientsRadiopharm Theranostics reported positive Phase 1 imaging results for RAD301 in healthy volunteers, patients wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL79Nw0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BQXX3F31.USD","BK4588","BK4112","BCDF","IE00B64PRP62.GBP","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014039.USD","BK7067","SG9999014005.SGD","RAD.AU","IE00BN0W2V16.EUR","NDAQ","IE00BQXX3D17.EUR","SG9999014021.USD","IE00B3QW5Z07.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666958797","title":"Radiopharm Theranostics - Significant Tumor Uptake Observed in All Evaluable Pancreatic Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666958797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666958797?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA58SJGN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587975","title":"Radiopharm Theranostics - Positive Safety and Favorable Biodistribution Observed in All Subjects Dosed with Rad301","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587975?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA58SJGN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666090582","title":"Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of Rad301 in Patients with Pancreatic Ductal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2666090582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666090582?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA58SJGN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051887","title":"Radiopharm Theranostics - no Dividends Paid or Declared for Year Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051887?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051884","title":"Radiopharm Theranostics - Prelim Loss for the Year Attributable up 50.3% to A$55.15 Mln for Year Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051884?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051881","title":"Radiopharm Theranostics - FY Prelim Revenue from Contracts with Customers A$2.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051881?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662718764","title":"Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of Betabart (Rv-01) in B7-H3 Expressing Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662718764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662718764?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:00","pubTimestamp":1787742001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA86WLSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286639","title":"Radiopharm Theranostics Advances 177Lu-Rad202 Phase 1 HEAT Trial to 180 mCi Dose Cohort After DSMC Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286639","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286639?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:03","pubTimestamp":1787223813,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics advances 177Lu-RAD202 Phase 1 HEAT trial to 180 mCi dose cohort after DSMC reviewRadiopharm Theranostics moved its Phase 1 HEAT trial of 177Lu-RAD202 into Cohort 4 following a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL8L5MBh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BCDF","BK7067","IE00BQXX3C00.GBP","BK4112","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","BK4585","SG9999014013.SGD","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","SG9999014021.USD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","NDAQ","IE00BKPKM429.USD","LU2095319765.USD","IE00BQXX3F31.USD","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660728687","title":"Radiopharm Theranostics - Rad202 Study Shows Clinical Proof-of-Concept with Positive Safety and Biodistribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2660728687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660728687?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332286","title":"Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-Rad202 Phase 1 Heat Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332286?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286382","title":"Radiopharm Theranostics - Advances Rad202 Phase 1 Trial to 180Mci Dose in Her2-Positive Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286382?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482805","title":"Radiopharm Teams up with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482805","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482805?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:31","pubTimestamp":1786966297,"startTime":"0","endTime":"0","summary":"Radiopharm teams up with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trialRadiopharm Theranostics entered a partnership with Siemens Healthineers to manufacture, distri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL3jXZZb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU2210149790.SGD","SG9999014039.USD","BK7067","SG9999014013.SGD","BK4588","RAD.AU","IE00BN0W2V16.EUR","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","BK4112","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660828634","title":"Radiopharm Theranostics - Rad101 Receives FDA Fast Track Designation for Brain Metastases Diagnosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2660828634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660828634?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:30","pubTimestamp":1786966200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA2CWZWY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660828624","title":"Radiopharm Theranostics - Schedules End-of-Phase 2 FDA Meeting for Rad101 Phase 3 Trial on Oct 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660828624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660828624?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:30","pubTimestamp":1786966200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA2CWZWY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101432","title":"Radiopharm Theranostics to Meet With US FDA on Phase 3 Brain Metastases Diagnosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101432","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101432?lang=en_us&edition=fundamental","pubTime":"2026-08-17 11:33","pubTimestamp":1786937616,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  will meet with the US Food and Drug Administration  on Oct. 1 to seek alignment on the design of a phase 3 trial to evaluate its RAD101 imaging agent in patients with suspected recurrence of brain metastases following radiotherapy, according to a Monday filing with the Australian bourse.The meeting will focus on the trial's design criteria, including the number of patients to be enrolled and the primary and secondary endpoints, per the filing.The FDA will also review data from a phase 2b trial of RAD 101, which showed 93% concordance between MRI and PET imaging of brain metastases in the targeted patient population, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK7067","RAD.AU","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660103689","title":"Radiopharm Theranostics Ltd-Rad to Meet with US FDA to Align on Rad 101 Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660103689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660103689?lang=en_us&edition=fundamental","pubTime":"2026-08-17 07:02","pubTimestamp":1786921352,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260816:nTUE7QS9KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":71,"code":"91000000","status":"200"}]}}